Harpgophytum procumbens for osteoarthritis and low back pain: A systematic review

被引：66

作者：

Gagnier J.J. ^{[1
,2
]}

Chrubasik S. ^{[3
,4
]}

Manheimer E. ^{[5
]}

机构：

[1] Dept. of Health Policy Mgmt./Eval., University of Toronto, Faculty of Medicine, Toronto, Ont.

[2] Canadian Coll. of Naturopathic Med., Toronto, Ont.

[3] Department of Forensic Medicine, University of Freiburg, Freiburg

[4] Herbal Medicines Res./Educ. Center, Faculty of Pharmacy, University of Sydney, Sydney, NSW

[5] Center for Integrative Medicine, University of Maryland, School of Medicine, Baltimore, MD

来源：

BMC Complementary and Alternative Medicine | / 4卷 / 1期

关键词：

Aqueous Extract; Tramadol; Acute Exacerbation; Rofecoxib; Moderate Evidence;

D O I：

10.1186/1472-6882-4-13

中图分类号：

学科分类号：

摘要：

Background: The objective of this review is to determine the effectiveness of Harpagophytum procumbens preparations in the treatment of various forms of musculoskeletal pain. Methods: Several databases and other sources were searched to identify randomized controlled trials, quasi-randomized controlled trials, and controlled clinical trials testing Harpagophytum preparations in adults suffering from pain due to osteoarthritis or low back pain. Results: Given the clinical heterogeneity and insufficient data for statistical pooling, trials were described in a narrative way, taking into consideration methodological quality scores. Twelve trials were included with six investigating osteoarthritis (two were identical trials), four low back pain, and three mixed-pain conditions. Conclusions: There is limited evidence for an ethanolic Harpagophytum extract containing less than <30 mg harpagoside per day in the treatment of knee and hip osteoarthritis. There is moderate evidence of effectiveness for (1) the use of a Harpagophytum powder at 60 mg harpagoside in the treatment of osteoarthritis of the spine, hip and knee; (2) the use of an aqueous Harpagophytum extract at a daily dose of 100 mg harpagoside in the treatment of acute exacerbations of chronic non-specific low back pain; and (3) the use of an aqueous extract of Harpagophytum procumbens at 60 mg harpagoside being non-inferior to 12.5 mg rofecoxib per day for chronic non-specific low-back pain (NSLBP) in the short term. Strong evidence exists for the use of an aqueous Harpagophytum extract at a daily dose equivalent of 50 mg harpagoside in the treatment of acute exacerbations of chronic NSLBP. © 2004 Gagnier et al; licensee BioMed Central Ltd.

引用

页数：10

共 43 条

[1]

(1996)

[2]

Lanhers M.C., Fleurentin J., Mortier F., Vinche A., Younos C., Antiinflammatory and analgesic effects of an aquous extract of Harpagophytum procumbens, Planta Medica, 58, pp. 117-123, (1992)

[3]

Chrubasik S., Wink N., Zur pharmakologischen Wirkung der Teufelskralle(Harpagophytum procumbens), Forschende Komplementärmedizin, 2, pp. 323-325, (1995)

[4]

Fiebich B.L., Heinrich M., Hiller K.-O., Kammerer N., Inhibition of TNF<sup>α</sup> synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69, Phytomedicine, 8, pp. 28-30, (2001)

[5]

Chrubasik S., Fiebich B., Black A., Pollak S., Treating low back pain with an extract of Harpagophytum that inhibits cytokine release, Eur. J. Anaesthesiol., 19, (2002)

[6]

Jang M.H., Lim S., Han S.M., Park H.J., Shin I., Kim J.W., Kim N.J., Lee J.S., Kim K.A., Kim C.J., Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929, J. Pharmacol. Sci., 93, pp. 367-371, (2003)

[7]

Schulze-Tanzil G., Hansen C., Shakibaei M., Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro, Arzneimittelforschung, 54, pp. 213-220, (2004)

[8]

Boje K., Lechtenberg M., Nahrstedt A., New and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastase, Planta Med., 69, pp. 820-825, (2003)

[9]

Robinson K., Dickerson K., Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed, Int. J. Epid., 31, pp. 150-153, (2002)

[10]

VanTulder M., Furlan A., Bombardier C., Bouter L., Updated method guidelines for systematicreviews in the cochrane collaboration back review group, Spine, 28, pp. 1290-1299, (2003)

← 1 2 3 4 5 →